KFS
VRTX icon

Keynote Financial Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Keynote Financial Services’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$600K Sell
1,207
-24
-2% -$10.6K 0.28% 92
2026
Q1 		$550K Buy
1,231
+65
+6% +$30.3K 0.29% 94
2025
Q4 		$529K Buy
1,166
+12
+1% +$5.17K 0.3% 89
2025
Q3 		$452K Buy
1,154
+9
+0.8% +$3.76K 0.27% 103
2025
Q2 		$510K Buy
1,145
+40
+4% +$18.4K 0.34% 80
2025
Q1 		$536K Buy
1,105
+20
+2% +$9.32K 0.38% 70
2024
Q4 		$437K Buy
1,085
+15
+1% +$6.95K 0.34% 81
2024
Q3 		$498K Buy
+1,070
New +$514K 0.38% 76

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Keynote Financial Services's VRTX Position: Q2 2026 in Review

Keynote Financial Services reduced its Vertex Pharmaceuticals (VRTX) stake by 1.9% in Q2 2026, selling an estimated $10.6K and leaving 1,207 shares worth $600K. The position accounts for 0.28% of the portfolio, ranked #92.

Keynote Financial Services first reported a position in VRTX in Q3 2024 and has held it in 8 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Keynote Financial Services held 1,207 shares of Vertex Pharmaceuticals worth $600K as of Q2 2026.
  • Keynote Financial Services sold 24 Vertex Pharmaceuticals shares in Q2 2026, an estimated $10.6K.
  • Vertex Pharmaceuticals made up 0.28% of Keynote Financial Services's portfolio in Q2 2026, its #92 holding.
  • Keynote Financial Services first reported a position in Vertex Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Keynote Financial Services's 13F filing for Q2 2026, filed 3 Aug 2026.